Long-PDE4D degradation attenuates left ventricular cardiomyocyte hypertrophic remodelling

The human heart is a relentless pump, but its rhythm depends on a delicate chemical conversation happening inside every single muscle cell. This conversation revolves around a tiny molecule called cyclic AMP, which acts as a messenger, carrying instructions from the surface of the cell to its inner machinery. When the heart needs to beat faster or stronger, these messengers flood specific areas of the cell to trigger the necessary changes. However, the cell also contains its own cleanup crew, enzymes that break down these messengers to keep the signal from becoming too loud or chaotic. In a healthy heart, this balance ensures that the signal to beat is strong where it needs to be, but contained where it shouldn't spread. When this system goes wrong, the heart can begin to thicken and stiffen in a dangerous process called hypertrophy, a condition that often leads to heart failure. For decades, doctors have tried to fix this by using drugs that block the cleanup crew entirely, but these blunt instruments often cause dangerous side effects because they disrupt the entire chemical landscape of the cell, not just the specific part that is broken.

A team of researchers has now explored a much more precise approach, one that does not just block the cleanup crew but removes specific members of it from the cell entirely. They focused on a particular type of cleanup enzyme known as long PDE4D, which acts like a gatekeeper in specific neighborhoods of the heart cell, particularly near the cell's outer wall and its command center. Using a novel tool called a PROTAC, which is a molecule designed to tag unwanted proteins for disposal, the scientists targeted these specific gatekeepers for removal. In experiments using adult rat heart cells and slices of human heart tissue, they found that getting rid of these specific enzymes allowed the chemical signals to flow more freely in the areas that control growth and gene expression, while leaving the signals that control the actual squeezing of the heart muscle completely untouched. The result was a heart cell that resisted the thickening caused by stress, without losing its ability to pump blood effectively.

The researchers began by designing a molecule named KTX-184, which works differently than traditional drugs. Instead of sitting in the active site of an enzyme to stop it from working, KTX-184 acts like a molecular bridge. One end of the bridge grabs onto the long PDE4D enzyme, while the other end grabs onto the cell's natural waste disposal system. This forces the cell to recognize the enzyme as trash and break it down. The team first tested this in laboratory-grown heart cells, confirming that the molecule successfully reduced the amount of long PDE4D protein without affecting other similar enzymes that the cell needs for different jobs. They observed that within just two hours of treatment, the levels of this specific enzyme began to drop, and the effect lasted for at least a day. Crucially, they showed that this process depended on the cell's waste disposal machinery, as blocking that system prevented the enzyme from being removed.

With the mechanism confirmed, the scientists moved to adult rat heart cells to see how this removal affected the cell's internal chemistry. They used a special imaging technique that allowed them to watch the chemical messengers in real time. They found that when they treated the cells with KTX-184, the chemical signals near the cell's outer wall and in the nucleus became much stronger when the cell was stimulated. This meant that the instructions for growth and adaptation were being heard more clearly. However, and this is a vital distinction, the signals that control the actual contraction of the heart muscle remained exactly the same. The cells did not beat harder or faster, nor did they show signs of the chaotic electrical activity that can lead to dangerous heart rhythms. The researchers also checked the tiny calcium spikes that drive the heartbeat and found them completely unchanged, proving that the drug did not interfere with the heart's pumping power.

The study then tested whether this approach could actually prevent the heart from becoming diseased. They exposed heart cells to a substance known to cause them to thicken and grow abnormally, a condition that mimics the stress of high blood pressure. In cells treated with the new molecule, the thickening was significantly reduced. The cells maintained their normal shape and size, and the tiny tubes that run through the heart muscle, which are essential for efficient signaling, stayed organized and intact. In contrast, cells treated with older, non-selective drugs did not show this protection. The researchers also looked at the genetic activity inside the cells and found that the new treatment stopped the activation of genes that drive heart disease, effectively turning off the switch for pathological growth.

To ensure these findings were not just a quirk of rat cells, the team repeated the experiments using human heart tissue. They took small slices of healthy human heart muscle and subjected them to mechanical stress, which causes the cells to stretch and thicken. When they added the new molecule to these human slices, it successfully prevented the cells from widening and becoming stiff, a key sign of heart failure. The human cells responded in the same way as the rat cells: the signals that control growth were amplified in a controlled way, while the signals for pumping remained steady. This suggests that the mechanism is conserved across species and could potentially work in people.

The implications of this work are significant because it offers a new way to think about treating heart disease. For years, the goal has been to boost the heart's performance, but this often comes with the risk of making the heart beat too hard or irregularly. This new approach suggests that by selectively removing specific proteins, it is possible to rewire the heart's internal communication network to stop it from growing in the wrong way, without disturbing the rhythm of the beat. The researchers emphasize that while these results are promising, they are based on cells and tissue slices, and the next step is to see if the molecule works safely in a living organism. Nevertheless, the study provides a clear proof of concept that targeted protein degradation can reshape heart cell signaling with a precision that traditional drugs cannot achieve, opening a potential path toward therapies that treat the root cause of heart remodeling without compromising the heart's essential function.